Among participants receiving the rifapentine-moxifloxacin regimen, higher pyrazinamide exposures were associated with increased risk of any grade 3-5 adverse events (OR 1.22 for every 100 gh/mL increase in AUC 024h , 95% CI 1.021.45) and treatment-related grade 3-5 adverse events (OR 1.27 for every 100 gh/mL increase in AUC 024h , 95% CI 1.041.55). There was no significant difference between quartiles of rifapentine exposure and any grade 3-5 adverse events, treatment related grade 3-5 adverse events, any serious adverse events, death, or tolerability. Participants without pharmacokinetic sampling were excluded from this figure. Percentages were calculated from the safety population for all safety outcomes except for premature discontinuation of the assigned regimen, which was calculated from the microbiologically eligible population with the exclusion of participants without PK sampling. For each quartile, the percentage of participants with safety outcomes are reported with number of events in parentheses.
